

Etienne Lengline

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7643585/publications.pdf>

Version: 2024-02-01

75
papers

2,563
citations

279798

23
h-index

206112

48
g-index

76
all docs

76
docs citations

76
times ranked

4243
citing authors

#	ARTICLE	IF	CITATIONS
1	A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. <i>Blood</i> , 2018, 131, 717-732.	1.4	240
2	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet, The</i> , 2020, 396, 1885-1894.	13.7	206
3	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i>-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4333-4342.	1.6	202
4	Managing critically ill hematology patients: Time to think differently. <i>Blood Reviews</i> , 2015, 29, 359-367.	5.7	166
5	Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. <i>Haematologica</i> , 2013, 98, e146-e148.	3.5	157
6	Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure. <i>Leukemia and Lymphoma</i> , 2013, 54, 1724-1729.	1.3	149
7	Clinical Impact of <i>NOTCH1</i> and/or <i>FBXW7</i> Mutations, <i>FLASH</i> Deletion, and <i>TCR</i> Status in Pediatric T-Cell Lymphoblastic Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1966-1973.	1.6	111
8	Acute Kidney Injury in Patients with Newly Diagnosed High-Grade Hematological Malignancies: Impact on Remission and Survival. <i>PLoS ONE</i> , 2013, 8, e55870.	2.5	108
9	Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure. <i>Leukemia and Lymphoma</i> , 2012, 53, 1352-1359.	1.3	93
10	How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?. <i>Blood Advances</i> , 2019, 3, 4238-4251.	5.2	72
11	Long-Term Immune Reconstitution and Infection Burden after Mismatched Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 507-517.	2.0	71
12	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
13	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
14	Critically ill allogeneic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. <i>Bone Marrow Transplantation</i> , 2018, 53, 1233-1241.	2.4	53
15	Complement C5 inhibition in patients with COVID-19 - a promising target?. <i>Haematologica</i> , 2020, 105, 2847-2850.	3.5	53
16	EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome. <i>Blood</i> , 2019, 134, 277-290.	1.4	48
17	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	1.4	48
18	Clinical phenotypes of critically ill COVID-19 patients. <i>Intensive Care Medicine</i> , 2020, 46, 1651-1652.	8.2	45

#	ARTICLE	IF	CITATIONS
19	Respiratory events at the earliest phase of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 2556-2563.	1.3	43
20	Epidemiology, clinical picture and long-term outcomes of <i>FIP1L1-CPDGFR</i> -positive myeloid neoplasm with eosinophilia: Data from 151 patients. <i>American Journal of Hematology</i> , 2020, 95, 1314-1323.	4.1	37
21	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2281-2288.	1.3	35
22	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	1.8	30
23	Unresponsive thrombotic thrombocytopenic purpura in critically ill adults. <i>Intensive Care Medicine</i> , 2013, 39, 1272-1281.	8.2	26
24	Epigenetic Silencing Affects Asparaginase Sensitivity and Predicts Outcome in T-ALL. <i>Clinical Cancer Research</i> , 2019, 25, 2483-2493.	7.0	25
25	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 1159-1168.	2.8	24
26	Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. <i>Lancet Oncology</i> , The, 2021, 22, e430-e434.	10.7	24
27	Acute kidney injury in critically ill allo-HSCT recipients. <i>Bone Marrow Transplantation</i> , 2014, 49, 1121-1122.	2.4	22
28	Identification of Distinct Immunophenotypes in Critically Ill Coronavirus Disease 2019 Patients. <i>Chest</i> , 2021, 159, 1884-1893.	0.8	20
29	Graft-Versus-Host Disease in Adolescents and Young Adults (15-24 Years Old) After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia in First Complete Remission. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 299-306.	1.3	19
30	Outcomes after intensive care unit admission of patients with newly diagnosed lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1240-1245.	1.3	18
31	Neutropenic Enterocolitis in Critically Ill Patients: Spectrum of the Disease and Risk of Invasive Fungal Disease. <i>Critical Care Medicine</i> , 2019, 47, 668-676.	0.9	18
32	Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2016, 172, 628-630.	2.5	16
33	Nationwide survey in France on the use of romiplostim in patients with refractory severe aplastic anemia. <i>Bone Marrow Transplantation</i> , 2019, 54, 1161-1163.	2.4	16
34	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
35	Plasma uric acid response to rasburicase: early marker for acute kidney injury in tumor lysis syndrome?. <i>Leukemia and Lymphoma</i> , 2014, 55, 2362-2367.	1.3	14
36	Impact of the source of hematopoietic stem cell in unrelated transplants: Comparison between 10/10, 9/10 HLA matched donors and cord blood. <i>American Journal of Hematology</i> , 2015, 90, 897-903.	4.1	14

#	ARTICLE	IF	CITATIONS
37	Gastrointestinal emergencies in critically ill cancer patients. <i>Journal of Critical Care</i> , 2017, 40, 69-75.	2.2	14
38	Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study. <i>Leukemia and Lymphoma</i> , 2018, 59, 1323-1331.	1.3	12
39	Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score. <i>Bone Marrow Transplantation</i> , 2020, 55, 1966-1974.	2.4	12
40	Eltrombopag for the Treatment of Aplastic Anemia in Europe. <i>Blood</i> , 2018, 132, 1304-1304.	1.4	12
41	Impact of a Recent Chemotherapy on the Duration and Intensity of the Norepinephrine Support During Septic Shock. <i>Shock</i> , 2013, 39, 138-143.	2.1	11
42	Urgent chemotherapy in hematological patients in the ICU. <i>Current Opinion in Critical Care</i> , 2015, 21, 1.	3.2	11
43	The effect of age in patients with acquired aplastic anaemia treated with immunosuppressive therapy: comparison of Adolescents and Young Adults with children and older adults. <i>British Journal of Haematology</i> , 2018, 183, 766-774.	2.5	11
44	Critically ill cancer patientâ€™s resuscitation: a Belgian/French societiesâ€™ consensus conference. <i>Intensive Care Medicine</i> , 2021, 47, 1063-1077.	8.2	11
45	Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 492-500.	2.3	10
46	Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy. <i>Leukemia</i> , 2021, 35, 712-723.	7.2	10
47	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	17.0	10
48	Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. <i>Annals of Intensive Care</i> , 2022, 12, 15.	4.6	10
49	Endothelial cells: major players in acute myeloid leukaemia. <i>Blood Reviews</i> , 2022, 54, 100932.	5.7	9
50	Top ten tips for the management of critically ill hematopoietic stem cell transplantation recipients. <i>Intensive Care Medicine</i> , 2019, 45, 384-387.	8.2	8
51	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	1.4	8
52	Predictors and outcomes associated with hydroxyurea sensitivity in acute myeloid leukemia patients with high hyperleukocytosis. <i>Leukemia and Lymphoma</i> , 2020, 61, 737-740.	1.3	7
53	Preclinical efficacy of humanized, nonâ€™FcÎ³R-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2020, 136, 1298-1302.	1.4	7
54	Worsening of Respiratory Status during Neutropenia Recovery in Noncritically Ill Hematological Patients: Results of a Prospective Multicenter Study. <i>Respiration</i> , 2015, 90, 229-234.	2.6	5

#	ARTICLE	IF	CITATIONS
55	Preempting critical care services for patients with hematological malignancies. Intensive Care Medicine, 2021, 47, 1140-1143.	8.2	5
56	Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemia. Modern Pathology, 2022, 35, 1227-1235.	5.5	5
57	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. Annals of Hematology, 2015, 94, 1859-1863.	1.8	4
58	How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network. Blood, 2015, 126, 456-456.	1.4	4
59	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. Blood, 2018, 132, 4040-4040.	1.4	4
60	Breast infiltration by relapsed acute lymphoblastic leukaemia on FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 811-812.	6.4	3
61	Successful nelarabine and venetoclax treatment of a relapsed/refractory mediastinal myeloid sarcoma with clonal TCR rearrangement. Anti-Cancer Drugs, 2021, 32, 1118-1122.	1.4	2
62	Prognostic Impact of Clonal Diversity in Acute Myeloid Leukemia (AML) Treated with Intensive Chemotherapy (IC). Blood, 2019, 134, 2700-2700.	1.4	1
63	Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia. Blood, 2016, 128, 2684-2684.	1.4	1
64	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. Blood, 2018, 132, 1428-1428.	1.4	1
65	Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. PLoS ONE, 2022, 17, e0270744.	2.5	1
66	Point-of-care ultrasound with handheld devices in hematology: a monocentric single-stage phase II study. Leukemia and Lymphoma, 2021, 62, 1379-1385.	1.3	0
67	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. Blood Cancer Journal, 2021, 11, 129.	6.2	0
68	Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients. Blood, 2013, 122, 2657-2657.	1.4	0
69	Intensive Care Management and Outcomes In Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Blood, 2013, 122, 4560-4560.	1.4	0
70	Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T-Cell Acute Lymphoblastic Leukemia. Blood, 2014, 124, 3723-3723.	1.4	0
71	R�animation des patients d�onco-h�matologie : nouvelles th�rapeutiques, nouvelles complications, nouveaux contrats d�admission. Bulletin De L'Academie Nationale De Medecine, 2015, 199, 293-312.	0.0	0
72	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. Blood, 2018, 132, 1537-1537.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Clinical Spectrum, Long-Term Outcomes and Predictors of Relapse after Imatinib Discontinuation in FIP1L1-Pdgfra-Associated Chronic Eosinophilic Leukemia: Data from 150 Patients. <i>Blood</i> , 2019, 134, 840-840.	1.4	0
74	Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	0
75	<i>Long-Term Outcome of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line</i> . <i>Blood</i> , 2020, 136, 44-45.	1.4	0